Cochlear Ltd (COH.xasx) is a medical device company headquartered in Sydney, Australia. Cochlear company designs, manufactures and supplies the Nucleus cochlear implant, the Hybrid electro-acoustic implant and the Baha bone conduction implant to over 180 countries. Cochlear Ltd holds over two-thirds of the worldwide hearing implant market, has provided more than 650,000 devices and has a global workforce of more than 4,000 people. Cochlear Ltd stock (COH.xasx) is listed on the Australian Securities Exchange Ltd (ASX) and had a market capitalisation of $13.66B (AUD) as of December 2021. The company manufactures principally in Australia and Sweden and has invested more than $2B (AUD) to date in research and development to improve its leading technology portfolio and outcomes for recipients. Cochlear announced its partnership with leading hearing health experts to conduct the largest ever international clinical study of an investigational cochlear implant that releases a glucocorticoid drug therapy directly to the cochlea. Cochlear joins leading Australian organisations in formalising its commitment to recognising and reconciling with Aboriginal and Torres Strait Islander peoples.
Cochlear Ltd (COH)
Stay updated with Cochlear Ltd (COH) share price, trends, and insights to guide your trading strategy. Stay informed with FP Markets France.